Clinical Trials Logo

Chronic Spontaneous Urticaria clinical trials

View clinical trials related to Chronic Spontaneous Urticaria.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06294288 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT05368285 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria

NCT ID: NCT04180488 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Start date: December 11, 2019
Phase: Phase 3
Study type: Interventional

Primary Objective: To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders) Secondary Objectives: To demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or hives, separately, at various timepoints To demonstrate the efficacy of dupilumab on angioedema To demonstrate the efficacy of dupilumab on urticaria control To demonstrate improvement in health-related quality of life and overall disease status and severity To evaluate the ability of dupilumab in reducing the proportion of patients who require treatment with oral corticosteroids (OCS) To evaluate safety outcome measures To evaluate immunogenicity of dupilumab

NCT ID: NCT03494881 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

Start date: July 30, 2019
Phase: Early Phase 1
Study type: Interventional

This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.